2017
Pacific Edge FY18 Interim Results
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has delivered a strong first half, year on year increase in revenue as it continues to build momentum and target large scale customers in the United States and other markets. [read more]
Pacific Edge recent share price increase
Pacific Edge has been asked today by the NZX about our recent share price increase. We confirm that, as of 27 November 2017, Pacific Edge Limited continues to comply with its continuous disclosure obligations under the NZX Main Board Listing Rules, including Listing Rule 10.1.1. [read more]
Pacific Edge Half Year Results to be Announced 29 November 2017
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), advises the release of its interim results for the six months ended 30 September 2017, on Wednesday 29 November 2017. [read more]
Pacific Edge Named 20th in Deloitte Fast50
The team at Dunedin cancer diagnostics company, Pacific Edge, is celebrating today after being named the 20th fastest growing company in the Deloitte Fast50 Awards, coming in with 324% growth in revenue over three years. [read more]
Pacific Edge Completes Shortfall Bookbuild and $21.3 Million Capital Raising
Pacific Edge Limited (NZX: PEB) (Pacific Edge) advises that it has completed the shortfall bookbuild component of its $21.3 million capital raise announced on 11 October 2017 (Offer), with support from both institutional and other eligible shareholders. All of the shares available under the Offer have now been taken up. [read more]
Rights Offer Component of Pacific Edge's $21.3 Million Offer Completed
Pacific Edge Limited (Pacific Edge) is pleased to advise it has completed the Rights Offer component of its underwritten 1 for 6 rights offer (Offer) of new ordinary shares in Pacific Edge (New Shares), which closed on 8 November 2017. [read more]
Pacific Edge Named in TIN Report Top 10 List
Pacific Edge’s global growth and positive revenue trajectory has been recognised with the cancer diagnostics company named number 6 in the TIN Top Ten List of Hot Emerging Companies for 2017. [read more]
Pacific Edge Announces $21.3 Million Capital Raising
Bladder cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has today announced its intention to raise approximately $21.3 million through a fully underwritten 1 for 6 pro-rata Rights Offer. [read more]
FY17 Cashflow Statement Reclassification
Pacific Edge Limited wishes to advise of a classification change within the FY17 Statement of Cash Flows on page 36 of the Pacific Edge Limited 2017 Annual Report. [read more]
Pacific Edge 2017 Annual Meeting Results
Pacific Edge held its Annual Meeting in Dunedin on 24 August 2017, updating shareholders on its strategic progress, particularly in the US which is the company’s primary opportunity. A positive and supportive group of shareholders attended both in Dunedin and on-line utilising an interactive meeting platform. [read more]
Pacific Edge 2017 Annual Meeting to Take Place on 24 August
Pacific Edge is holding its Annual Shareholders' Meeting on 25 August at the Dunedin Public Art Gallery. For more information including Proxy Form, read on. [read more]
Cxbladder Test Suite Adopted by MidCentral DHB
Cancer diagnostics company, Pacific Edge has signed a commercial agreement with the MidCentral District Health Board (MCDHB) extending its use to the full suite of Cxbladder cancer tests for use across the clinical pathway for the detection, management and monitoring of bladder cancer patients. [read more]
Pacific Edge Releases Annual Report for 12 Months Ending 31 March 2017
Pacific Edge is pleased to issue its Annual Report for the 12 months ending 31 March 2017. Click the links below to read the report and the Annual Review Shareholder Letter. [read more]
Pacific Edge Full Year Results to 31 March 2017
Steady growth in sales and laboratory throughput; strong progress on targeted transformational customers [read more]
Pacific Edge Full Year Results to be Announced 24 May 2017
Pacific Edge Limited (NZX:PEB) advises that it intends to announce its full year results for the financial year ended 31 March 2017 on Wednesday 24 May 2017, prior to 10am NZST. [read more]
Request for Director Nominations
Pacific Edge Limited advises that the opening date for Director Nominations is Thursday 11th May 2017 and that the closing date for Director Nominations is Wednesday 19th July 2017. [read more]
GenomeWeb: Pacific Edge Bladder Cancer Recurrence Test Outperforms Others in Head-to-Head Comparison
Pacific Edge and Cxbladder profiled in GenomeWeb feature story [read more]
Callaghan Innovation Growth Grant for Pacific Edge
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to advise that it has received an additional grant of up to $3 million to its existing Growth Grant from Callaghan Innovation to enable further research and development of its leading edge cancer diagnostics technology. [read more]
Significant Increase in Clinical Utility from Use of Cxbladder
An international study demonstrates compelling changes in urologists’ clinical decisions, with use of Cxbladder Triage and Cxbladder Detect leading to fewer total tests and less invasive procedures, implying a reduction in healthcare costs and an improved experience and outcome for patients. [read more]
Cxbladder Monitor Significantly Outperforms FDA Approved Urine Tests for Bladder Cancer
The prestigious international journal Urological Oncology, has accepted for publication a scientific and clinical paper validating the superior performance of Pacific Edge’s Cxbladder Monitor test for the surveillance of patients who are being managed following treatment for bladder cancer. [read more]
Pacific Edge Undertakes $8m Share Placement
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has undertaken a $8.0 million share placement to institutional and other select investors in New Zealand. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.